RecruitingNCT05294978
EyeConic: Qualification for Cone-Optogenetics
Qualification for Cone-Optogenetics (EyeConic)
Sponsor
Institute of Molecular and Clinical Ophthalmology Basel
Enrollment
1,000 participants
Start Date
Jul 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
Eligibility
Inclusion Criteria5
- Diagnosis of generalized IRD
- Low vision as defined as visual acuity worse or equal to 0.05 (or 20/400) in the study eye
- Availability of macular optical coherence tomography (OCT)
- Normal ophthalmic findings
- Availability of macular optical coherence tomography (OCT)
Exclusion Criteria2
- Other eye diseases with a significant effect on vision or retinal structure
- Extraocular disease affecting retinal structure such as neurodegenerative diseases
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTOptical coherence tomography (OCT)
Data of macular optical coherence tomography (OCT)
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05294978
Related Trials
Natural History Study of Inherited Retinal Diseases
NCT070855331 location
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
NCT068529636 locations
SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)
NCT061779771 location
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
NCT063198721 location
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
NCT064558265 locations